Urea Kinetics in Patients on Regular Dialysis Treatment before and after Treatment with Recombinant Human Erythropoietin

2015 ◽  
pp. 149-155 ◽  
Author(s):  
E. Zehnter ◽  
M. Pollok ◽  
D. Ziegenhagen ◽  
P. Bramsiepe ◽  
F. Longere ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Dialysis Treatment ◽  
Human Erythropoietin ◽  
Before And After ◽  
Urea Kinetics ◽  
Regular Dialysis Treatment

Safe Employment of Recombinant Human Erythropoietin in Pregnancy in Two Anuric Patients on Regular Dialysis Treatment

Renal Failure ◽  
1995 ◽  
Vol 17 (1) ◽  
pp. 73-76
Author(s):  
Anna Rachele Rocca ◽  
Sandro Mazzaferro ◽  
Giovanni Stirati ◽  
Elena Bilancioni ◽  
Claudio Giorlandino
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Dialysis Treatment ◽  
Human Erythropoietin ◽  
Regular Dialysis Treatment ◽  
In Pregnancy

Quality of Life Improvements in Capd Patients Treated with Subcutaneously Administered Erythropoietin for Anemia

1992 ◽  
Vol 12 (1) ◽  
pp. 40-42 ◽  
Author(s):  
Juliet Auer ◽  
Gail Simon ◽  
Judith Stevens ◽  
Paul Griffiths ◽  
Deborah Howarth ◽  
...  
Keyword(s):  
Social Life ◽  
Recombinant Human Erythropoietin ◽  
Nottingham Health Profile ◽  
Hemodialysis Patients ◽  
Health Profile ◽  
Emotional Wellbeing ◽  
Household Tasks ◽  
Human Erythropoietin ◽  
Before And After

Twenty -two continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 48 years, at 3 U.K. renal units were assessed with the Nottingham Health Profile (N HP) before and after treatment with recombinant human erythropoietin (r-HuEPO). Mean (SD) hemoglobin (Hb) at baseline was 7.5 (1.0) gIn/dl and 10.8 (1.5) gIn/dl at retest. There were significant improvements in energy (p<0.0001), social life (p<0.005), relationships at home (p<0.05) and leisure pursuits (p<0.05). Twelve patients, mean age 51 years, who had already completed more than 9 months on r-HuEPO treatment were reassessed to determine the changes sustained. Mean (SD) Hb at second retest was 12.8 (1.3) gm/dl. Improvement in energy continued to be significant, and emotional wellbeing showed further improvement. Problems with household tasks, which had not shown significant improvement at Test B, were now considerably reduced (p=0.016). The study showed far-reaching benefits similar to those reported in hemodialysis patients, in a population with a higher mean age and higher potential coexisting illness or disability than most reported hemodialysis studies.

Autonomic Neuropathy in Hemodialysis Patients Treated with Recombinant Human Erythropoietin

1996 ◽  
Vol 19 (10) ◽  
pp. 574-577 ◽  
Author(s):  
O.O. Stojcheva-Taneva ◽  
M.H. Polenakovic
Keyword(s):  
Blood Pressure ◽  
Autonomic Dysfunction ◽  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Exercise Heart Rate ◽  
Control Group ◽  
Human Erythropoietin ◽  
Group I ◽  
Before And After

Autonomic nervous system (ANS) function was evaluated in hemodialysis patients treated with recombinant human erythropoietin (rHu-EPO) before and after therapy, in an effort to evaluate the role of anemia in the genesis of autonomic dysfunction in chronic renal failure (CRF). Studies were conducted using a battery of five cardiovascular reflex tests: Valsalva maneuver, handgrip exercise, heart rate response to standing (30:15 index), post-Valsalva rise in blood pressure and postural drop in blood pressure. The patients were divided into two groups: group I consisted of 14 patients on maintenance hemodialysis treated with rHu-EPO for one year, and group II - 13 hemodialysis patients treated with rHu-EPO for two years. The results of the tests were compared before and after the correction of anemia by rHu-EPO in each group, as well as with the control group of ten healthy subjects. Data show that renal anemia is not implicated in the genesis of ANS dysfunction in hemodialysis patients, since correction of same by rHu-EPO does not improve the autonomic dysfunction.

Hematocrit Influence on Peritoneal Dialysis Effectiveness during Recombinant Human Erythropoietin Treatment in Patients with Chronic Renal Failure

1993 ◽  
Vol 13 (2_suppl) ◽  
pp. 550-552 ◽  
Author(s):  
Andrzej Ksiazek ◽  
Elzbieta Baranowska-Daca
Keyword(s):  
Peritoneal Dialysis ◽  
Recombinant Human Erythropoietin ◽  
Glucose Absorption ◽  
Mean Value ◽  
Protein Loss ◽  
Peritoneal Equilibration Test ◽  
Sodium Potassium ◽  
Human Erythropoietin ◽  
Before And After ◽  
Erythropoietin Treatment

Seven intermittent peritoneal dialysis (IPD) patients were investigated before and after correction of anemia with recombinant human erythropoietin (r-HuEPO). When hematocrit exceeded 300/0, the peritoneal equilibration test was performed at 1, 2, 4, 8 hours. Correction of anemia was associated with a mean value Increment In creatinine and phosphate clearance In 1 and 2-hour dwells. Differences In clearance of sodium, potassium, and urea In protein loss and glucose absorption before and after r-HuEPO therapy were not statistically significant. Increased creatinine and phosphate clearance during short dwells can be effected in IPD patients.

Injections of recombinant human erythropoietin increases lactate influx into erythrocytes

2004 ◽  
Vol 97 (1) ◽  
pp. 326-332 ◽  
Author(s):  
Philippe Connes ◽  
Corinne Caillaud ◽  
Jacques Mercier ◽  
Didier Bouix ◽  
Jean François Casties
Keyword(s):  
Placebo Group ◽  
Recombinant Human Erythropoietin ◽  
Lactate Concentration ◽  
Band 3 ◽  
Monocarboxylate Transporter ◽  
Maximal Velocity ◽  
Lactate Transport ◽  
Human Erythropoietin ◽  
Before And After ◽  
Lactate Uptake

Previous studies showed that erythropoietin not only increases erythrocyte production but is also essential in both the synthesis and the good functioning of several erythrocyte membrane proteins, including band 3. It is still unknown whether anion and/or H+ fluxes are modified by erythropoietin. This study aimed to evaluate the effect of recombinant human erythropoietin (rHuEPO) injections on lactate transport into erythrocytes via band 3 and H+-monocarboxylate transporter MCT-1, two proteins involved in lactate exchange. Nine athletes received subcutaneous rHuEPO (50 U/kg body mass 3 times a week for 4 wk), and seven athletes received a saline solution (placebo group). All subjects were also supplemented with oral iron and vitamins B9 and B12. Lactate transport into erythrocytes was studied before and after the rHuEPO treatment at different lactate concentrations (1.6, 8.1, 41, and 81.1 mM). After treatment, MCT-1 lactate uptake was increased at 1.6, 41 ( P < 0.01), and 81.1 mM lactate concentration ( P < 0.001) although lactate uptake via band 3 and nonionic diffusion were unchanged. MCT-1 maximal velocity increased in the rHuEPO group ( P < 0.05), reaching higher values than in the placebo group ( P < 0.05) after treatment. Our results show that rHuEPO injections increased MCT-1 lactate influx at low and high lactate concentrations. The increase in MCT-1 maximal velocity suggests that rHuEPO may stimulate MCT-1 synthesis during erythrocyte formation in bone marrow.

scholarly journals Bioenergetics of the Calf Muscle in Friedreich Ataxia Patients Measured by 31P-MRS Before and After Treatment with Recombinant Human Erythropoietin

PLoS ONE ◽  
2013 ◽  
Vol 8 (7) ◽  
pp. e69229 ◽  
Author(s):  
Wolfgang Nachbauer ◽  
Sylvia Boesch ◽  
Rainer Schneider ◽  
Andreas Eigentler ◽  
Julia Wanschitz ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Friedreich Ataxia ◽  
Calf Muscle ◽  
31P Mrs ◽  
Human Erythropoietin ◽  
Before And After
Sign in / Sign up

Export Citation Format

Share Document